Alzheimer's disease and dementia<unk>  is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors. One guideline recommends<unk>  or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.<unk>  has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.<unk>  when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of<unk>  with donepezil in those with moderate-to-severe dementia. Psychiatry Bipolar disorder<unk>  has been investigated as a possible augmentation strategy for depression in bipolar disorder but meta-analytic evidence does not support its clinical utility. Autism Effects in autism are unclear.
Memantine
Rivastigmine
Donepezil
Nusinersen
Bromperidol decanoate
Perhexiline
Carbidopa/levodopa
Rilonacept